Epstein-Barr Virus-Positive Natural Killer/T-Cell Lymphoma

Area of Science:

• Oncology
• Hematology
• Genetics

Background:

• Extranodal natural killer/T-cell lymphoma, nasal type (ENKL) is a rare, aggressive Non-Hodgkin lymphoma.
• ENKL is strongly associated with Epstein-Barr virus infection and prevalent in Asia and Latin America.
• Current standard treatments for ENKL are not fully established, necessitating further research.

Purpose of the Study:

• To review genetic alterations in ENKL and their implications for therapeutic targets.
• To highlight recent findings on biologic markers and novel therapeutic strategies for ENKL.
• To provide insights into the mechanisms and potential treatments for ENKL.

Main Methods:

• Review of gene expression profiling and sequencing techniques to identify genetic alterations.
• Analysis of existing literature on ENKL pathogenesis, treatment, and outcomes.
• Synthesis of information on genetic mutations, epigenetic dysregulation, and therapeutic approaches.

Main Results:

• Frequent deletion of chromosome 6q21 silences tumor suppressor genes in ENKL.
• Novel mutations activate oncogenic pathways like JAK/STAT, NF-κB, and MAPK.
• Non-anthracycline regimens and anti-PD-1 antibodies show promise for advanced/refractory ENKL.

Conclusions:

• Genetic alterations and epigenetic dysregulation are key to ENKL pathogenesis.
• Targeting these alterations and pathways may lead to novel therapeutic strategies.
• Optimizing combined radiotherapy and chemotherapy, and identifying superior non-anthracycline regimens are ongoing research priorities.